Vieth R, McCarten K, Norwich K H
Department of Clinical Biochemistry, University of Toronto, Ontario, Canada.
Am J Physiol. 1990 May;258(5 Pt 1):E780-9. doi: 10.1152/ajpendo.1990.258.5.E780.
To understand the relationships among 1) the dose of 25-hydroxyvitamin D [25(OH)D] in vivo, 2) the activity of 1-hydroxylase in renal mitochondria, and 3) the production of 1,25-dihydroxyvitamin D [1,25(OH)2D] in vivo, we gave rats different chronic or acute doses of 25-hydroxyvitamin D3 [25(OH)D3]. We followed the metabolism of intracardially administered [25-hydroxy-26,27-methyl-3H]cholecalciferol [25(OH)[3H]D3] for 24 h before killing by measuring extracts of serum by chromatography. Specific activity of 1-hydroxylase in kidney was measured at death. In rats given 0-2,000 pmol 25(OH)D3 chronically by mouth, there was a dose-dependent decline in the percent of serum radioactivity made up of 1,25-dihydroxy-[26,27-methyl-3H]cholecalciferol [1,25(OH)2[3H]D3] as well as a decline in mitochondrial 1-hydroxylase, and these correlated significantly (r = 0.83, P less than 0.001). Serum %1,25(OH)2[3H]D3 in this experiment ranged from 0.8 to 42%. A small part of this range could be accounted for by a faster metabolic clearance rate (MCR) of 1,25(OH)2D3 from rats supplemented with 25(OH)D3 (MCR, 2.12 +/- 0.10 ml/min) compared with rats restricted in vitamin D (MCR, 0.94 +/- 0.06 ml/min, P less than 0.001). The activity of 1-hydroxylase was by far the major factor determining serum %1,25(OH)2[3H]D3. When different acute doses of 25(OH)D3 were given to rats with identical specific activities of 1-hydroxylase, the resulting 1,25(OH)2D3 concentrations in serum correlated with the 25(OH)D3 dose (r = 0.99, P less than 0.001). We conclude that the behavior of 1-hydroxylase in vivo is analogous to the classic behavior in vitro of an enzyme functioning below its Michaelis constant (Km). The amount of 1-hydroxylase present in renal mitochondria determines the fraction (not simply the quantity) of 25(OH)D metabolized to 1,25(OH)2D3 in vivo.
为了解1)体内25-羟基维生素D [25(OH)D] 的剂量、2)肾线粒体中1-羟化酶的活性以及3)体内1,25-二羟基维生素D [1,25(OH)2D] 的生成之间的关系,我们给大鼠不同的慢性或急性剂量的25-羟基维生素D3 [25(OH)D3]。在处死前,通过色谱法测量血清提取物,追踪心内注射的[25-羟基-26,27-甲基-3H]胆钙化醇 [25(OH)[3H]D3] 的代谢24小时。在处死时测量肾脏中1-羟化酶的比活性。给大鼠经口长期给予0 - 2000 pmol 25(OH)D3,由1,25-二羟基-[26,27-甲基-3H]胆钙化醇 [1,25(OH)2[3H]D3] 构成的血清放射性百分比呈剂量依赖性下降,同时线粒体1-羟化酶也下降,且二者显著相关(r = 0.83,P < 0.001)。本实验中血清1,25(OH)2[3H]D3的百分比范围为0.8%至42%。与维生素D受限的大鼠相比,补充25(OH)D3的大鼠中1,25(OH)2D3的代谢清除率(MCR)更快(MCR,2.12 ± 0.10 ml/min 与0.94 ± 0.06 ml/min,P < 0.001),这可以解释该范围的一小部分。1-羟化酶的活性是决定血清1,25(OH)2[3H]D3百分比的主要因素。当给具有相同1-羟化酶比活性的大鼠给予不同急性剂量的25(OH)D3时,血清中产生的1,25(OH)2D3浓度与25(OH)D3剂量相关(r = 0.99,P < 0.001)。我们得出结论,体内1-羟化酶的行为类似于体外一种在其米氏常数(Km)以下起作用的酶的经典行为。肾线粒体中存在的1-羟化酶的量决定了体内25(OH)D代谢为1,25(OH)2D3的比例(而非仅仅是数量)。